Article
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
JCI insight - 23 Mar 2017
Mondello Patrizia, Brea Elliott J, De Stanchina Elisa, Toska Eneda, Chang Aaron Y, Fennell Myles, Seshan Venkatraman, Garippa Ralph, Scheinberg David A, Baselga José, Wendel Hans-Guido, Younes Anas
Abstract excerpt
Diffuse large B cell lymphoma (DLBCL) frequently harbors genetic alterations that activate the B cell receptor (BCR) and TLR pathways, which converge to activate NF-κB. While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial and of a short duration. Here, we demonstrated that MyD88 silencing enhanced ibrutinib efficacy in DLBCL cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.